| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 164,859 | 114,449 | 81,732 | 62,898 |
| Cost of goods sold | 1,585 | 1,521 | 4,679 | 1,626 |
| Research and development | 51,890 | 49,362 | 46,889 | 51,679 |
| Selling, general and administrative | 86,453 | 76,216 | 72,838 | 65,619 |
| In-process research and development | 0 | 0 | - | - |
| Restructuring | 0 | 0 | - | 123 |
| Total operating expenses | 139,928 | 127,099 | 124,406 | 119,047 |
| Operating income (loss) | 24,931 | -12,650 | -42,674 | -56,149 |
| Interest income | 3,047 | 3,287 | 3,795 | 3,570 |
| Interest expense | 2,751 | 2,846 | 2,857 | 2,777 |
| Other income (expense), net | 487 | -526 | 549 | 520 |
| Total other income, net | 783 | -85 | 1,487 | 1,313 |
| Income (loss) from continuing operations before income tax | 25,714 | -12,735 | -41,187 | -54,836 |
| Income tax (provision) benefit on continuing operations | 8 | 20 | 39 | -84 |
| Income (loss) from continuing operations, net of tax | 25,706 | -12,755 | -41,226 | -54,752 |
| Loss from discontinued operations, net of tax | 0 | 0 | - | -59 |
| Net income (loss) | 25,706 | -12,755 | -41,226 | -54,811 |
| Foreign currency translation (loss) gain | -284 | 268 | -686 | -803 |
| Unrealized gain (loss) on marketable debt securities | 42 | -237 | -77 | 1,421 |
| Comprehensive income (loss) | 25,464 | -12,724 | -41,989 | -54,193 |
| Net income (loss) per common share, basic (in dollars per share) | 0.29 | -0.14 | -0.47 | -0.7 |
| Net income (loss) per common share, diluted (in dollars per share) | 0.28 | -0.14 | -0.47 | -0.7 |
| Weighted average common shares outstanding, basic (in shares) | 89,230,420 | 88,945,624 | 88,355,973 | 77,779,379 |
| Weighted average common shares outstanding, diluted (in shares) | 102,618,560 | 88,945,624 | 88,355,973 | 77,779,379 |
Travere Therapeutics, Inc. (TVTX)
Travere Therapeutics, Inc. (TVTX)